RxDoctor Payments Data

Erik Thyssen, MD

Gastroenterology · Creve Coeur, MONPI 1750495099

Payments from drug & device makers

$7,740in general payments, 2019–2025

Across 419 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$1K
  • Sanofi$547
  • Pfizer$513
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$453
  • Bristol Myers Squibb$226
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$7,63099%
  • Education$841%
  • Gifts$150%
  • Entertainment$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,740 in reported general payments places this provider in the 70th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$439,447
Medicare patients
681
Services billed
13,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab23$552,462
CreonLipase/Protease/Amylase20$47,548
LinzessLinaclotide52$39,894
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C118$16,881
Mesalamine23$15,878
TrulancePlecanatide17$14,554
MotegrityPrucalopride Succinate25$13,039
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates191$12,432
Budesonide EcBudesonide38$5,727
SutabSod Sulf/Pot Chloride/Mag Sulf22$3,546
Mesalamine ErMesalamine17$3,511
Methscopolamine Bromide15$3,504
Budesonide DrBudesonide28$3,266
Omeprazole195$1,881
Sodium Chloride0.9 % Sodium Chloride20$1,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,421$552,46223 claims
AbbVieCreon, Linzess$2,962$87,44272 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu, Trulance$453$31,435135 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$128$13,03925 claims
Braintree Laboratories, Inc.Sutab$36$3,54622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Creve Coeur

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →